Register  /  Login               
Print this article
- 01/17/2018

Rumors on a possible deal between Juno Therapeutics and Celgene Corp.

Pharma Horizon

Juno Therapeutics Inc.’s shares  rose more than 44 percent after news about the interest  of Celgene Corp.  to buy the Seattle-based drugmaker came out.  Juno Therapeutics Inc is a leader in the effort to use the immune system to treat cancer.

If a deal is reached, it would continue a recent string of acquisitions by Celgene, which is under pressure to find ways to offset generic competition for top-selling cancer treatment Revlimid.

Celgene, based in Summit, New Jersey, agreed last week to buy closely held Impact Biomedicines for $1.1 billion upfront, gaining an experimental blood-cancer treatment.

If the deal will be closed it would rank among Celgene’s largest-ever deals.


Read further: Bloomberg

About us

tks | publisher, event organiser,
media agency

Viale Brianza, 22
20127 - Milano - Italy
Tel. +39 02 26809375